Metabolic brings in $12m through options
Monday, 25 August, 2003
Metabolic Pharmaceuticals (ASX:MBP) is today heralding a recently finalised exercise of listed options had brought the company AUD$12 million.
Although the listed $0.20 options were exercisable over a four-year period ending on July 31, most were exercised in the last three months, releasing at least $10 million, said managing director Chris Belyea. The company now has $14 million in cash, and no borrowings, with a market capitalisation of $260 million at the close of trading on Aug 22.
Belyea said the funds would primarily be put toward Metabolic's obesity drug AOD9604, with Phase IIb clinical studies due to commence in October.
At the time of writing, Metabolic shares were trading at $1.30, up 8.3 per cent.
Simulated microgravity affects sleep, physiological rhythms
The simulated effects of microgravity significantly affect rhythmicity and sleep in humans, which...
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
